VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine
May 10, 2018 07:30 ET
|
VBI Vaccines, Inc.
CMV neutralizing antibodies against fibroblast cell infection induced in 100% of subjects who received the highest doseSafe and well-tolerated at all doses with no safety signals observedConference...
VBI Vaccines Announces First Quarter 2018 Financial Results and Provides Corporate Update
May 01, 2018 08:00 ET
|
VBI Vaccines, Inc.
-- Enrollment completed in PROTECT Phase 3 clinical study of Sci-B-Vac® Hepatitis B Vaccine -- -- Key upcoming milestones in 2018 for lead eVLP vaccine candidates, VBI-1501 for prevention of...
VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
April 17, 2018 08:00 ET
|
VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationLow-dose study arm: enrollment completeIntermediate-dose study arm: enrollment...
VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901
January 17, 2018 08:00 ET
|
VBI Vaccines, Inc.
Two-part Phase 1/2a study of VBI-1901 to enroll patients with recurrent GBM Part A: Dose escalation to enroll up to 18 patientsPart B: Subsequent extension of optimal dose to enroll up to 10...
VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017
November 10, 2017 08:00 ET
|
VBI Vaccines, Inc.
New data confirms use of intradermal delivery of eVLPs may be a potent “off-the-shelf” immunotherapy vaccinePoster presentation at the Society for Immunotherapy of Cancer’s (SITC) 32nd Annual Meeting...
VBI Vaccines Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 Million
October 30, 2017 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 Million
October 26, 2017 09:29 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares
October 25, 2017 16:01 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (TSX:VBV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...